Please enable JavaScript to continue using this application.

Compare $INBX vs $KLRA | Chartloom

Compare

$INBX vs $KLRA

Inhibrx Biosciences Inc · Kailera Therapeutics Inc

INBX

Inhibrx Biosciences Inc

KLRA

Kailera Therapeutics Inc

Compare $INBX vs $KLRA

Comparing Inhibrx Biosciences Inc and Kailera Therapeutics Inc

INBXInhibrx Biosciences Inc

KLRAKailera Therapeutics Inc

INBXInhibrx Biosciences Inc

Market cap

$1.39B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-100.0%

YTD performance

26.6%

52W performance

182.7%

FCF yield

-9.5%

KLRAKailera Therapeutics Inc

Market cap

$1.50B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-55.3%

52W performance

-55.3%

FCF yield

0.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

INBX

KLRA

Detailed metrics comparison

INBX

Inhibrx Biosciences Inc

KLRA

Kailera Therapeutics Inc

Market Cap

INBX$1.39B

KLRA$1.50B

Enterprise Value

INBX$1.44B

KLRA$1.37B

Price

INBX$95.01

KLRA$11.61

P/E Ratio

INBXN/A

KLRAN/A

P/S Ratio

INBX1,019.62x

KLRA0.00x

EV/Sales

INBX1,050.29x

KLRA0.00x

EV/EBITDA

INBX0.85x

KLRA0.00x

P/B Ratio

INBX178.59x

KLRA1.20x

P/FCF Ratio

INBXN/A

KLRAN/A

EV/FCF

INBX-10.89x

KLRA0.00x

PEG Ratio

INBXN/A

KLRAN/A

Forward P/E (NTM)

INBXN/A

KLRAN/A

Forward P/S (NTM)

INBXN/A

KLRAN/A

Revenue (TTM)

INBX$0

KLRA$0

Revenue Growth (YoY)

INBX-100.0%

KLRAN/A

Forward Rev Growth

INBX282.8%

KLRA275.8%

Gross Margin (TTM)

INBX0.0%

KLRA0.0%

Operating Margin (TTM)

INBX0.0%

KLRA0.0%

EBITDA Margin (TTM)

INBX0.0%

KLRA0.0%

Net Margin (TTM)

INBX0.0%

KLRA0.0%

FCF Margin (TTM)

INBXN/A

KLRAN/A

Net Income (TTM)

INBX$-138M

KLRA$-190M

FCF (TTM)

INBX$-132M

KLRA$0

EPS (TTM)

INBX-$8.82

KLRA-$1.86

ROE (TTM)

INBX-26956.0%

KLRA0.0%

ROA (TTM)

INBX-8348.0%

KLRA0.0%

ROIC (TTM)

INBX-9241.0%

KLRA0.0%

Cash

INBX$133M

KLRA$130M

Debt

INBX$176M

KLRA$0

Net Cash/Debt

INBX$-43M

KLRA$130M

Current Ratio (TTM)

INBX5.07x

KLRA11.11x

Quick Ratio (TTM)

INBX4.76x

KLRA11.04x

Debt/Equity (TTM)

INBX12.58x

KLRA0.00x

Debt/Assets (TTM)

INBX0.0%

KLRA0.0%

Interest Coverage (TTM)

INBXN/A

KLRAN/A

Net Debt/EBITDA (TTM)

INBX0.00x

KLRA0.00x

Beta

INBX3.17

KLRA2.22

52W Performance

INBX182.7%

KLRA-55.3%

YTD Performance

INBX26.6%

KLRA-55.3%

% from 52W High

INBX-38.8%

KLRA-58.9%

% from 52W Low

INBX237.4%

KLRA19.0%

Asset Turnover (TTM)

INBX0.01x

KLRA0.00x

FCF Yield (TTM)

INBX-9.5%

KLRA0.0%

Earnings Yield (TTM)

INBX-9.9%

KLRA-12.6%

Dividend Yield (TTM)

INBXN/A

KLRAN/A

Rule of 40

INBX-100.0

KLRA0.0

EV/GP/RG

INBXN/A

KLRAN/A

Ticker research

View INBX research View KLRA research

Metric	INBX Inhibrx Biosciences Inc	KLRA Kailera Therapeutics Inc
Market & Valuation
Market Cap	$1.39B	$1.50B
Enterprise Value	$1.44B	$1.37B
Price	$95.01	$11.61
P/E Ratio	N/A	N/A
P/S Ratio	1,019.62x	0.00x
EV/Sales	1,050.29x	0.00x
EV/EBITDA	0.85x	0.00x
P/B Ratio	178.59x	1.20x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.89x	0.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	-100.0%	N/A
Forward Rev Growth	282.8%	275.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-138M	$-190M
FCF (TTM)	$-132M	$0
EPS (TTM)	-$8.82	-$1.86
ROE (TTM)	-26956.0%	0.0%
ROA (TTM)	-8348.0%	0.0%
ROIC (TTM)	-9241.0%	0.0%
Financial Health
Cash	$133M	$130M
Debt	$176M	$0
Net Cash/Debt	$-43M	$130M
Current Ratio (TTM)	5.07x	11.11x
Quick Ratio (TTM)	4.76x	11.04x
Debt/Equity (TTM)	12.58x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.17	2.22
52W Performance	182.7%	-55.3%
YTD Performance	26.6%	-55.3%
% from 52W High	-38.8%	-58.9%
% from 52W Low	237.4%	19.0%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-9.5%	0.0%
Earnings Yield (TTM)	-9.9%	-12.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View INBX research	View KLRA research

Valuation

P/S Ratio

KLRA

0.00x

INBX

1,019.62x

EV/FCF

INBX

-10.89x

KLRA

0.00x

Growth & revenue

Revenue Growth TTM

INBX

-100.0%

Forward Revenue Growth

INBX

282.8%

KLRA

275.8%

Profitability & performance

Gross Margin

INBX

0.0%

KLRA

0.0%

ROE

KLRA

0.0%

INBX

-26956.0%

FCF Yield %

KLRA

0.0%

INBX

-9.5%

52-Week Performance

INBX

182.7%

KLRA

-55.3%

Detailed metrics comparison

INBX

Inhibrx Biosciences Inc

KLRA

Kailera Therapeutics Inc

Market Cap

INBX$1.39B

KLRA$1.50B

Enterprise Value

INBX$1.44B

KLRA$1.37B

Price

INBX$95.01

KLRA$11.61

P/E Ratio

INBXN/A

KLRAN/A

P/S Ratio

INBX1,019.62x

KLRA0.00x

EV/Sales

INBX1,050.29x

KLRA0.00x

EV/EBITDA

INBX0.85x

KLRA0.00x

P/B Ratio

INBX178.59x

KLRA1.20x

P/FCF Ratio

INBXN/A

KLRAN/A

EV/FCF

INBX-10.89x

KLRA0.00x

PEG Ratio

INBXN/A

KLRAN/A

Forward P/E (NTM)

INBXN/A

KLRAN/A

Forward P/S (NTM)

INBXN/A

KLRAN/A

Revenue (TTM)

INBX$0

KLRA$0

Revenue Growth (YoY)

INBX-100.0%

KLRAN/A

Forward Rev Growth

INBX282.8%

KLRA275.8%

Gross Margin (TTM)

INBX0.0%

KLRA0.0%

Operating Margin (TTM)

INBX0.0%

KLRA0.0%

EBITDA Margin (TTM)

INBX0.0%

KLRA0.0%

Net Margin (TTM)

INBX0.0%

KLRA0.0%

FCF Margin (TTM)

INBXN/A

KLRAN/A

Net Income (TTM)

INBX$-138M

KLRA$-190M

FCF (TTM)

INBX$-132M

KLRA$0

EPS (TTM)

INBX-$8.82

KLRA-$1.86

ROE (TTM)

INBX-26956.0%

KLRA0.0%

ROA (TTM)

INBX-8348.0%

KLRA0.0%

ROIC (TTM)

INBX-9241.0%

KLRA0.0%

Cash

INBX$133M

KLRA$130M

Debt

INBX$176M

KLRA$0

Net Cash/Debt

INBX$-43M

KLRA$130M

Current Ratio (TTM)

INBX5.07x

KLRA11.11x

Quick Ratio (TTM)

INBX4.76x

KLRA11.04x

Debt/Equity (TTM)

INBX12.58x

KLRA0.00x

Debt/Assets (TTM)

INBX0.0%

KLRA0.0%

Interest Coverage (TTM)

INBXN/A

KLRAN/A

Net Debt/EBITDA (TTM)

INBX0.00x

KLRA0.00x

Beta

INBX3.17

KLRA2.22

52W Performance

INBX182.7%

KLRA-55.3%

YTD Performance

INBX26.6%

KLRA-55.3%

% from 52W High

INBX-38.8%

KLRA-58.9%

% from 52W Low

INBX237.4%

KLRA19.0%

Asset Turnover (TTM)

INBX0.01x

KLRA0.00x

FCF Yield (TTM)

INBX-9.5%

KLRA0.0%

Earnings Yield (TTM)

INBX-9.9%

KLRA-12.6%

Dividend Yield (TTM)

INBXN/A

KLRAN/A

Rule of 40

INBX-100.0

KLRA0.0

EV/GP/RG

INBXN/A

KLRAN/A

Ticker research

View INBX research View KLRA research

Metric	INBX Inhibrx Biosciences Inc	KLRA Kailera Therapeutics Inc
Market & Valuation
Market Cap	$1.39B	$1.50B
Enterprise Value	$1.44B	$1.37B
Price	$95.01	$11.61
P/E Ratio	N/A	N/A
P/S Ratio	1,019.62x	0.00x
EV/Sales	1,050.29x	0.00x
EV/EBITDA	0.85x	0.00x
P/B Ratio	178.59x	1.20x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.89x	0.00x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	-100.0%	N/A
Forward Rev Growth	282.8%	275.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-138M	$-190M
FCF (TTM)	$-132M	$0
EPS (TTM)	-$8.82	-$1.86
ROE (TTM)	-26956.0%	0.0%
ROA (TTM)	-8348.0%	0.0%
ROIC (TTM)	-9241.0%	0.0%
Financial Health
Cash	$133M	$130M
Debt	$176M	$0
Net Cash/Debt	$-43M	$130M
Current Ratio (TTM)	5.07x	11.11x
Quick Ratio (TTM)	4.76x	11.04x
Debt/Equity (TTM)	12.58x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.17	2.22
52W Performance	182.7%	-55.3%
YTD Performance	26.6%	-55.3%
% from 52W High	-38.8%	-58.9%
% from 52W Low	237.4%	19.0%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-9.5%	0.0%
Earnings Yield (TTM)	-9.9%	-12.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-100.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View INBX research	View KLRA research